# Specified Drug-use Surveillance of Fabhalta Capsules

> **NCT06606314** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06606314
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06606314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06606314, "Specified Drug-use Surveillance of Fabhalta Capsules". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06606314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*